Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
prednisone + hydroxychloroquine + aspirin + enoxaparin
- Development stage
- Phase 1
- Lead developer
- Qilu Hospital of Shandong University
- Modality
- Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
This therapeutic combination regimen is evaluated by Qilu Hospital of Shandong University for the management of pregnant women with systemic lupus erythematosus (SLE). The regimen consists of a baseline of prednisone and hydroxychloroquine, supplemented with the antiplatelet agent aspirin and the low molecular weight heparin (LMWH) enoxaparin. This "anticoagulation" strategy is specifically designed to improve pregnancy outcomes—such as reducing the incidence of preeclampsia, fetal loss, and premature delivery—in SLE patients, particularly those stratified by antiphospholipid antibody (aPL) status. The combination addresses the multi-organ autoimmune activity of SLE while simultaneously mitigating the prothrombotic risks associated with pregnancy and lupus-related antibodies.
- Other names
- AnticoagulationAnticoagulation therapy for SLE in pregnancy
02
Targets
ATIII (Antithrombin III)F2 (Thrombin)F10 (Factor Xa)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)GR (Glucocorticoid receptor)TLR7 (Toll-like receptor 7)TLR9 (Toll-like receptor 9)
Beyond the preview
Go deeper on prednisone + hydroxychloroquine + aspirin + enoxaparin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on prednisone + hydroxychloroquine + aspirin + enoxaparin.